Kingdon Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Kingdon Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-179,600	Closed	-$20.6M	–	196
2014 Q4	$20.6M	Sell	179,600 -12,100	-6%	-$1.47M	0.9%	36
2014 Q3	$29.9M	Buy	191,700 +166,700	+667%	+$24.2M	1.34%	12
2014 Q2	$3.08M	Buy	+25,000	New	+$2.76M	0.12%	157
2014 Q1	–	Sell	-80,400	Closed	-$7.23M	–	231
2013 Q4	$7.23M	Sell	80,400 -18,300	-19%	-$1.46M	0.33%	95
2013 Q3	$6.6M	Buy	98,700 +40,000	+68%	+$2.76M	0.32%	90
2013 Q2	$3.88M	Buy	+58,700	New	+$3.36M	0.23%	116

Other funds holding SLXP

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kingdon Capital Management's SLXP Position: Q1 2015 in Review

Kingdon Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 179,600 shares — an estimated $20.6M sold.

Kingdon Capital Management first reported a position in SLXP in Q2 2013 and held it in 6 quarters. The position peaked at $29.9M in Q3 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

Kingdon Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
Kingdon Capital Management sold 179,600 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $20.6M.
Kingdon Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 6 quarters.
Kingdon Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $29.9M in Q3 2014.
298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Kingdon Capital Management's 13F filing for Q1 2015, filed 15 May 2015.